Lower insulin prices from Danish diabetes giant Novo Nordisk (NOV: N) will be welcomed by millions of Americans with diabetes who struggle to afford their medicine.
The firm said it would offer authorized generic versions of its NovoLog and NovoLog Mix brands through the newly-established US affiliate Novo Nordisk Pharma.
The products will be offered at half the price of the branded versions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze